Mechanisms of the HER3 Signaling Pathway

During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first article of a 2-part series.

In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.

CAR T-cell therapy showed efficacy in relapsed large B-cell lymphoma across age groups, including patients 70 and 80 years or older.

In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.

NKTR-255 with CD19 chimeric antigen receptor T-cell therapy improved 6-month complete response rates in relapsed/refractory large B-cell lymphoma.

Anakinra failed to reduce cytokine release syndrome or immune effector cell–associated neurotoxicity in patients with large B-cell lymphoma receiving liso-cel.